Publications by authors named "Carlo Finelli"

Claim this Profile
R
Real-World Treatment Patterns, Clinical Outcomes, and Costs in Patients with Higher-Risk Myelodysplastic Syndromes Across France, Germany, and the United Kingdom.
Mark Drummond, Carlo Finelli, Fjoralba Kristo, Sneha S Kelkar, Shelby Corman

J Blood Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers.
Elena Crisà, Daniela Cilloni, Marta Riva, Enrico Balleari, Daniela Barraco, Carlo Finelli

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms.
Eleonora Ceneri, Alessia De Stefano, Irene Casalin, Carlo Finelli, Antonio Curti

Adv Biol Regul· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular taxonomy of myelodysplastic syndromes and its clinical implications.
Elsa Bernard, Robert P Hasserjian, Peter L Greenberg, Juan E Arango Ossa, Maria Creignou, Carlo Finelli

Blood· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study.
Elena Crisà, Elvira Mora, Ulrich Germing, Cecile Bally, Maria Diez Campelo, Carlo Finelli

Leukemia· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Maria Sirenko, Elsa Bernard, Maria Creignou, Dylan Domenico, Andrea Farina, Carlo Finelli

Blood· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
Matteo Sarocchi, Junmin Li, Xiao Li, Depei Wu, Efreen Montaño Figueroa, Carlo Finelli

Br J Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
Aleix Noguera-Castells, Ignacio Campillo-Marcos, Veronica Davalos, Carlos A García-Prieto, David Valcárcel, Carlo Finelli

Br J Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study.
Phillip Scheinberg, Carlo Finelli, Efreen H Montaňo-Figueroa, Carlos Vallejo, Lalita Norasetthada

Lancet Haematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of Cancer Stem Cells in Normal and Dysplastic/Leukemic Human Blood.
Alessia De Stefano, Alessandra Cappellini, Irene Casalin, Stefania Paolini, Sarah Parisi, Carlo Finelli

Methods Mol Biol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression.
Irene Casalin, Alessia De Stefano, Eleonora Ceneri, Alessandra Cappellini, Carlo Finelli

Adv Biol Regul· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Luca Lanino, Francesco Restuccia, Alessandra Perego, Marta Ubezio, Bruno Fattizzo, Carlo Finelli

Am J Hematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Sara Mongiorgi, Alessia De Stefano, Stefano Ratti, Valentina Indio, Annalisa Astolfi, Carlo Finelli

Clin Epigenetics· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience.
Giulia Calabretto, Enrico Attardi, Antonella Teramo, Valentina Trimarco, Samuela Carraro, Carlo Finelli

Leukemia· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Elsa Bernard, Heinz Tuechler, Peter L Greenberg, Robert P Hasserjian, Juan E Arango Ossa, Carlo Finelli

NEJM Evid· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Rami S Komrokji, Uwe Platzbecker, Pierre Fenaux, Amer M Zeidan, Guillermo Garcia-Manero, Carlo Finelli

Leukemia· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the rationale for red cell transfusion in myelodysplastic syndrome patients: emerging data and future insights.
Carlo Finelli, Sarah Parisi, Stefania Paolini

Expert Rev Hematol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy.
Yao-Chung Liu, Junsu Kwon, Emiliano Fabiani, Zhijian Xiao, Yanjing V Liu, Carlo Finelli

N Engl J Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Guillermo Garcia-Manero, Ghulam J Mufti, Pierre Fenaux, Rena Buckstein, Valeria Santini, Carlo Finelli

Blood· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients.
Sarah Parisi, Carlo Finelli

J Blood Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox.
Giuseppe A Palumbo, Sara Galimberti, Wilma Barcellini, Daniela Cilloni, Nicola Di Renzo, Carlo Finelli

Front Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine.
Carlo Pescia, Francesca Boggio, Giorgio Alberto Croci, Ramona Cassin, Marco Barella, Carlo Finelli

J Clin Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Marino Clavio, Elena Crisà, Maurizio Miglino, Fabio Guolo, Manuela Ceccarelli, Carlo Finelli

Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Elsa Bernard, Yasuhito Nannya, Robert P Hasserjian, Sean M Devlin, Heinz Tuechler, Carlo Finelli

Nat Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Elsa Bernard, Yasuhito Nannya, Robert P Hasserjian, Sean M Devlin, Heinz Tuechler, Carlo Finelli

Nat Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis